↓ Skip to main content

Dove Medical Press

Article Metrics

Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies

Overview of attention for article published in Drug Design, Development and Therapy, January 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
40 Mendeley
Title
Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies
Published in
Drug Design, Development and Therapy, January 2017
DOI 10.2147/dddt.s119036
Pubmed ID
Authors

Alex Françoso, Patricia Ucelli Simioni

Abstract

Colorectal cancer is considered a disease of the elderly population. Since the number of geriatric patients continues to rise, monoclonal antibody therapy is the most promising therapy in the recent research. Presently, the monoclonal antibodies most frequently used in the treatment of colorectal tumors are bevacizumab, cetuximab, panitumumab, and ramucirumab. Bevacizumab is a monoclonal antibody that acts on VEGF. Cetuximab and panitumumab act on EGFR. Ramucirumab binds directly to the ligand-binding pocket of VEGFR-2 to block the binding of VEGF-A, VEGF-C, and VEGF-D. These monoclonal antibodies, alone or in association with radiotherapy or chemotherapy, are presenting good results and are increasing patient survival, despite the side effects. Due to the limited number of molecules available, several studies are trying to develop new monoclonal antibodies for the treatment of colorectal tumors. Among those being studied, some recent molecules are in phase I and/or II trials and are yielding advantageous results, such as anti-DR5, anti-Fn14, anti-IGF-1R, anti-EGFR, anti-NRP1, and anti-A33 antibodies. This has been successful in reducing side effects and in treating nonresponsive patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 20%
Student > Master 6 15%
Student > Doctoral Student 4 10%
Researcher 4 10%
Student > Postgraduate 3 8%
Other 7 18%
Unknown 8 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 18%
Immunology and Microbiology 5 13%
Medicine and Dentistry 5 13%
Agricultural and Biological Sciences 5 13%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Other 7 18%
Unknown 8 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2018.
All research outputs
#4,270,668
of 14,803,679 outputs
Outputs from Drug Design, Development and Therapy
#230
of 1,520 outputs
Outputs of similar age
#121,588
of 378,517 outputs
Outputs of similar age from Drug Design, Development and Therapy
#7
of 38 outputs
Altmetric has tracked 14,803,679 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,520 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,517 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.